JPH0468588B2 - - Google Patents
Info
- Publication number
- JPH0468588B2 JPH0468588B2 JP56171467A JP17146781A JPH0468588B2 JP H0468588 B2 JPH0468588 B2 JP H0468588B2 JP 56171467 A JP56171467 A JP 56171467A JP 17146781 A JP17146781 A JP 17146781A JP H0468588 B2 JPH0468588 B2 JP H0468588B2
- Authority
- JP
- Japan
- Prior art keywords
- tube
- substance
- immobilized
- reagent
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 230000004520 agglutination Effects 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 230000001900 immune effect Effects 0.000 claims description 8
- 239000011325 microbead Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 208000030452 Transient pseudohypoaldosteronism Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
本発明は、免疫学的凝集反応を利用してヒトま
たは動物の体液中の成分を検出ないし測定する免
疫学的検査管に関する。抗原と抗体との反応を利
用してそのいずれか一方を免疫学的に検出または
定量する場合に、測定したい物質に結合する側の
物質を適当な大きさの担体粒子に固定させてお
き、その粒子が被測定物質の存在下に凝集を起こ
す現象を利用して高感度の測定を行なう方法は免
疫学的臨床検査の重要な手段となつている。ま
た、逆に測定したい物質を粒子に固定しておき、
その被測定物質と特異的に反応する抗原または抗
体の存在による被測定物質固定化粒子の凝集が、
被測定物質の存在により阻止されることにより被
測定物質を検出または定量する方法も免疫学的臨
床検査において広く用いられている。
従来、免疫活性物質固定化微粒子が検体液中の
被測定成分との反応により凝集するか否か、また
は予め準備された試薬と免疫活性物質固定化微粒
子との反応による凝集を検体液中の被測定成分が
阻止するか否かという判定は、主に平板上あるい
はマイクロプレート上で検体と凝集反応用試薬を
混合することにより行なわれている。しかし平板
上で凝集反応は非常に迅速であるが感度が低い。
一方マイクロプレート上での凝集反応は感度が高
いが、判定に要する時間が２時間以上と長い。
本発明者らは、これら従来の欠点を解決すべ
く、高感度で判定時間が短く、かつ簡便な検査管
について検討した結果、本発明に到達した。
すなわち本発明は担体としてポリマーマイクロ
ビーズを用いた免疫学的凝集反応試薬を、毛細管
内で凍結乾燥させてなる免疫学的検査管により達
成できる。
本発明で用いられる凝集反応試薬とは、測定し
たい物質に特異的に結合する物質あるいは測定し
たい物質を担体に固定化させたものである。これ
ら担体に固定化させる物質としては、例えば梅毒
トレポネーマ抗原、リウマチ因子、Ｂ型肝炎表面
抗原（HBs抗原）、HBs抗原に対する抗体（抗
HBs抗体）、トキソプラズマ抗原、ストレプトリ
ジン−Ｏ、抗ストレプトリジンＯ抗体、マイコプ
ラズマ抗原、ヒト繊毛性ゴナドトロピン
（HCG）、抗HCG抗体、熱凝集ヒト免疫グロブリ
ンＧ、核蛋白、デオキシ核酸、抗Ｃ反応性蛋白抗
体、エストロゲン、抗エストロゲン抗体、補体成
分（C1q、C1r、C1s、C2、C3、C4、C5、C6、
C7、C8、C9）およびそれらに対する抗体などの
免疫活性物質が挙げられる。担体としては、ポリ
スチレンラテツクス、その他ポリマーマイクロビ
ーズが挙げられる。
具体的には、特願昭55−58677で用いられるア
クリロニトリルまたはメタクリロニトリルを主成
分とする平均直径0.03ないし10μｍの微粒子を加
水分解して得られる微粒子であり、さらに好まし
くはグルタルアルデヒドで活性化された微粒子で
ある。
免疫活性物質の担体への固定化は、物理吸着イ
オン結合または共有結合によつて行なわれる。
本発明で用いる毛細管は0.5〜５mm、好ましく
は約１mmの均一な内径を有し、さらに好ましくは
50〜100mmの長さのガラスまたはポリメチルメタ
クリレート、ポリスチレン、ポリカーボネート、
ポリ塩化ビニル、ポリスルホンなどのプラスチツ
クを材質とする透明な管状物である。
この毛細管は、検体あるいは凝集反応用試薬を
一定量吸入する目的ピストンあるいはキヤツプ状
ピペツター、さらに目盛を備えている方が好まし
い。
本発明では毛細管に凝集反応試薬を注入した
後、該試薬を凍結乾燥する。凍結乾燥法は通常の
方法で構わないが、液体窒素中で凍結させる方が
好ましい。凝集反応は、血清または血漿などの検
体を毛細管に注入し、凝集反応試薬と混合させて
行なう。凍結乾燥した凝集反応用試薬は、検体と
混合させる前に水で溶解させることが好ましい。
凝集反応には、従来から知られている凝集反応用
添加剤を添加することももちろん可能であ。検体
と試薬を充分に混合させた後、毛細管をほぼ水平
方向に静置させると、数十分後には（＋）像と
（−）像を判別できる沈降像が得られる。
本発明は、Ｕ字型マイクロプレートと同程度の
高感度を示し、しかも判定に要する時間を短縮で
きるという優れた検査管であり、また凍結乾燥し
た凝集反応用試薬は保存性が良いため、予め調整
しておくと、検体を毛細管に注入するだけで検査
ができるという利点もある。
以下、実施例を挙げて本発明をさらに具体的に
説明する。
参考例 １
内径1.2mm、高さ75mmのガラス製ヘマトクリツ
ト管中に、梅毒HA抗原（富士臓器製薬）の抗原
感作ヒツジ血球浮遊液を10μ採り、液体窒素中
で凍結し減圧乾燥した。管中に蒸留水10μを注
入して感作血球を再分散した後、血清希釈液で希
釈した血清を10μ注入し、管軸方向に管を上下
して充分に混合し、水平面上に静置した。30分後
の判定結果を表１および第１図に示す。第１図
中、ａは陽性（＋）、ｂは陰性（−）を示す。な
お、マイクロプレート（Ｕ字型）の場合の沈降像
を比較対照として第２図に示す。第２図は第１図
と同様ａが陽性、ｂが陰性を示す。マイクロプレ
ートの場合は、判定に18時間要した。
The present invention relates to an immunological test tube that detects or measures components in human or animal body fluids using immunological agglutination reactions. When using the reaction between an antigen and an antibody to immunologically detect or quantify either one of them, the substance that binds to the substance to be measured is immobilized on carrier particles of an appropriate size. A highly sensitive measurement method that utilizes the phenomenon of particles aggregating in the presence of a substance to be measured has become an important means for immunological clinical testing. Alternatively, you can fix the substance you want to measure on particles,
Aggregation of particles immobilized with the analyte due to the presence of antigens or antibodies that specifically react with the analyte
Methods for detecting or quantifying a analyte by inhibiting the presence of the analyte are also widely used in immunological clinical tests. Conventionally, it has been determined whether immunoactive substance-immobilized microparticles aggregate due to a reaction with a component to be measured in a sample fluid, or whether the immunoactive substance-immobilized microparticles aggregate due to a reaction between a pre-prepared reagent and immunoactive substance-immobilized microparticles in a sample fluid. Determination as to whether a component to be measured inhibits or not is mainly made by mixing a specimen and an agglutination reaction reagent on a flat plate or microplate. However, although the agglutination reaction is very rapid on a flat plate, the sensitivity is low.
On the other hand, agglutination reactions on microplates have high sensitivity, but the time required for determination is long, 2 hours or more. In order to solve these conventional drawbacks, the present inventors have studied a test tube that is highly sensitive, has a short determination time, and is simple, and as a result, has arrived at the present invention. That is, the present invention can be achieved by using an immunological test tube formed by freeze-drying an immunological agglutination reaction reagent using polymer microbeads as a carrier in a capillary tube. The agglutination reaction reagent used in the present invention is a substance that specifically binds to a substance to be measured or a substance to be measured that is immobilized on a carrier. Substances to be immobilized on these carriers include, for example, Treponema pallidum antigen, rheumatoid factor, hepatitis B surface antigen (HBs antigen), and antibodies against HBs antigen (antibodies).
HBs antibody), Toxoplasma antigen, streptolysin-O, anti-streptolysin O antibody, mycoplasma antigen, human ciliated gonadotropin (HCG), anti-HCG antibody, heat-agglutinated human immunoglobulin G, nuclear protein, deoxynucleic acid, anti-C reactivity Protein antibodies, estrogen, anti-estrogen antibodies, complement components (C1q, C1r, C1s, C2, C3, C4, C5, C6,
C7, C8, C9) and immunologically active substances such as antibodies against them. Examples of carriers include polystyrene latex and other polymer microbeads. Specifically, it is a fine particle obtained by hydrolyzing fine particles with an average diameter of 0.03 to 10 μm that are mainly composed of acrylonitrile or methacrylonitrile used in Japanese Patent Application No. 58677/1982, and more preferably activated with glutaraldehyde. It is a fine particle. Immobilization of the immunologically active substance onto the carrier is performed by physically adsorbed ionic bonds or covalent bonds. The capillary used in the present invention has a uniform inner diameter of 0.5 to 5 mm, preferably about 1 mm, more preferably
50-100mm length glass or polymethyl methacrylate, polystyrene, polycarbonate,
It is a transparent tube made of plastic such as polyvinyl chloride or polysulfone. This capillary tube is preferably equipped with a piston or a cap-shaped pipettor for aspirating a fixed amount of a specimen or a reagent for an agglutination reaction, and a scale. In the present invention, after injecting an agglutination reaction reagent into a capillary tube, the reagent is freeze-dried. Freeze-drying may be a conventional method, but freezing in liquid nitrogen is preferable. The agglutination reaction is performed by injecting a sample such as serum or plasma into a capillary tube and mixing it with an agglutination reaction reagent. The freeze-dried agglutination reaction reagent is preferably dissolved in water before being mixed with the specimen.
It is of course possible to add conventionally known additives for aggregation reactions to the aggregation reaction. After thoroughly mixing the sample and reagent, if the capillary tube is left standing in a substantially horizontal direction, a sedimentation image that can distinguish between a (+) image and a (-) image is obtained several tens of minutes later. The present invention is an excellent test tube that exhibits high sensitivity comparable to that of a U-shaped microplate and can shorten the time required for determination.Furthermore, the freeze-dried reagent for agglutination reaction has a good shelf life, so it can be prepared in advance. Once adjusted, there is the advantage that testing can be performed simply by injecting the sample into a capillary tube. Hereinafter, the present invention will be explained in more detail with reference to Examples. Reference Example 1 In a glass hematocrit tube with an inner diameter of 1.2 mm and a height of 75 mm, 10 μm of a suspension of sheep blood cells sensitized with syphilis HA antigen (Fuji Organ Pharmaceutical Co., Ltd.) was taken, frozen in liquid nitrogen, and dried under reduced pressure. Inject 10μ of distilled water into the tube to redisperse the sensitized blood cells, then inject 10μ of serum diluted with serum diluent, mix thoroughly by moving the tube up and down in the axial direction, and leave it on a horizontal surface. did. The determination results after 30 minutes are shown in Table 1 and FIG. In FIG. 1, a indicates positive (+) and b indicates negative (-). In addition, the sedimentation image in the case of a microplate (U-shaped) is shown in FIG. 2 for comparison. In FIG. 2, as in FIG. 1, a indicates positive and b indicates negative. In the case of microplates, it took 18 hours for the determination.
【表】
＊ 管内における最終希釈倍率
実施例 １
参考例１と同様のヘマトクリツト管中に特願昭
55−58677に記載のBSA固定化ポリマーマイクロ
ビーズ分散液10μを採り、凍結乾燥した。管中
に蒸留水10μを注入してBSA固定化ポリマーマ
イクロビーズを再分散した後、200μgAb／mlの抗
BSA抗血清（兎）のリン酸緩衝生理食塩水溶液
10μを採つて管軸方向に上下して充分に混合
し、水平面上に静置した。なお、陰性対照として
抗BSA抗血清（兎）をBSAのリン酸緩衝生理食
塩水溶液（BSA1mg／ml）で同率に希釈し使用し
た。20分後に判定すると、リン酸緩衝生理食塩水
溶液にBSAを添加した陰性対照は第１図の（−）
像を示し、BSAを添加しなかつた試料は（＋）
像を示した。
実施例 ２
ヘマトクリツト管中に特願昭55−58677に記載
の梅毒抗原固定化ポリマーマイクロビーズ分散液
を10μ採り、管両端にキヤツプを付けて冷蔵庫
中に保存した。管両端のキヤツプを取り、血清希
釈液により40倍に希釈したTPHA力価1280の血
清を10μ採つて管軸方向に上下して充分に混合
し、水平面上に静置した。対照として陰性血清で
同じ操作をくり返した。20分後に判定すると、陽
性血清では（＋）像が、陰性血清では（−）像が
得られた。[Table] * Final dilution ratio in the tube Example 1 In a hematocrit tube similar to Reference Example 1,
10μ of the BSA-immobilized polymer microbead dispersion described in No. 55-58677 was taken and freeze-dried. After redispersing the BSA-immobilized polymer microbeads by injecting 10μ of distilled water into the tube, 200μg Ab/ml of anti-microbeads was added.
BSA antiserum (rabbit) in phosphate buffered saline
A 10 μm sample was taken, mixed thoroughly by moving it up and down in the direction of the tube axis, and then placed on a horizontal surface. As a negative control, anti-BSA antiserum (rabbit) was diluted to the same ratio with a phosphate buffered saline solution of BSA (BSA 1 mg/ml) and used. When judged after 20 minutes, the negative control (-) in Figure 1, in which BSA was added to the phosphate buffered saline solution
Samples with no BSA added are (+)
The image was shown. Example 2 10μ of the syphilis antigen-immobilized polymer microbead dispersion described in Japanese Patent Application No. 58677/1986 was placed in a hematocrit tube, caps were attached to both ends of the tube, and the tube was stored in a refrigerator. Caps were removed from both ends of the tube, 10μ of serum with a TPHA titer of 1280 diluted 40 times with a serum diluent was taken, mixed thoroughly by moving up and down in the tube axis direction, and the tube was left standing on a horizontal surface. The same procedure was repeated using negative serum as a control. When judged after 20 minutes, a (+) image was obtained for positive serum, and a (-) image was obtained for negative serum.
第１図は本発明による検査結果を示す拡大縦断
面図であり、第２図は従来法のマイクロプレート
による方法の検査結果を示す拡大平面図である。
各々ａは＋像、ｂは−像を示す。
FIG. 1 is an enlarged vertical sectional view showing the test results according to the present invention, and FIG. 2 is an enlarged plan view showing the test results of the conventional method using a microplate.
In each case, a represents a + image and b represents a − image.
Claims (1)
免疫学的凝集反応試薬を、毛細管内で凍結乾燥さ
せてなる免疫学的検査管。1. An immunological test tube obtained by freeze-drying an immunological agglutination reaction reagent using polymer microbeads as a carrier in a capillary tube.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17146781A JPS5873866A (en) | 1981-10-28 | 1981-10-28 | Immunological method for detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17146781A JPS5873866A (en) | 1981-10-28 | 1981-10-28 | Immunological method for detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5873866A JPS5873866A (en) | 1983-05-04 |
| JPH0468588B2 true JPH0468588B2 (en) | 1992-11-02 |
Family
ID=15923641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17146781A Granted JPS5873866A (en) | 1981-10-28 | 1981-10-28 | Immunological method for detection |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5873866A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0616045B2 (en) * | 1985-10-24 | 1994-03-02 | ヒユ−・ブイ・コツチンガム | Liquid particle reagent agglutination slide |
| WO1990007716A1 (en) * | 1988-12-23 | 1990-07-12 | Toray Industries, Inc. | Immunological inspection tube |
| CA2023803C (en) * | 1989-08-23 | 1999-05-18 | Takeshi Miyazaki | Method for measuring an immunologically active material and apparatus suitable for practicing said method |
| EP0466170B1 (en) * | 1990-07-13 | 1997-11-05 | Canon Kabushiki Kaisha | Detection reagent |
| US7850917B2 (en) | 2008-03-11 | 2010-12-14 | Ortho-Clinical Diagnostics, Inc. | Particle agglutination in a tip |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4117920Y1 (en) * | 1964-03-09 | 1966-08-19 | ||
| JPS52117420A (en) * | 1976-03-25 | 1977-10-01 | Hoffmann La Roche | Preparation of latex binding serum physiologically determining substance |
-
1981
- 1981-10-28 JP JP17146781A patent/JPS5873866A/en active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4117920Y1 (en) * | 1964-03-09 | 1966-08-19 | ||
| JPS52117420A (en) * | 1976-03-25 | 1977-10-01 | Hoffmann La Roche | Preparation of latex binding serum physiologically determining substance |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5873866A (en) | 1983-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5236826A (en) | Immunoassay for the detection or quantitation of an analyte | |
| AU724443B2 (en) | Assays using reference microparticles | |
| CN1061142C (en) | Light scatter-based immunoassay without particle self aggregation | |
| US4521521A (en) | Particle reagent size distribution measurements for immunoassay | |
| EP0724156A1 (en) | Kit for immunologically assaying biological substance and assay process | |
| WO1987003690A1 (en) | Particle-bound binding component immunoassay | |
| US4716123A (en) | Solid phase biological diagnostic assay via visual observation as enhanced by Mie scattering | |
| EP0070527B1 (en) | Method of assaying biologically active substances and labelling agents therefor | |
| Gella et al. | Latex agglutination procedures in immunodiagnosis | |
| EP0768530A1 (en) | Process for assaying biological substance | |
| JP2021505887A (en) | Lateral flow assays and methods for detecting high concentrations of analytes | |
| JP4086266B2 (en) | Immunoassay method | |
| CN1404577A (en) | Immunological assay reagents and assay method | |
| JP2005077301A (en) | Immunological detection carrier and measuring method | |
| JPH0468588B2 (en) | ||
| US4792527A (en) | Method of assaying biologically active substances and labelling agents therefor | |
| US5686252A (en) | Immunoassay method utilizing zeta potential and immunoassay kit | |
| JPH08262024A (en) | Kit for immunoassay of in vivo substance and immunoassay method | |
| JP3749959B2 (en) | Measuring method of test substance using magnetic particles and measuring instrument used for the method | |
| JP3220546B2 (en) | Method for measuring antigen or antibody in the presence of immune complex | |
| JP2004325414A (en) | Method and kit for measuring immunity | |
| JP4556605B2 (en) | Target substance measurement method and reagent | |
| JPH09304386A (en) | Manufacture of immunity diagnostic drug and immunity diagnostic drug obtained | |
| Singer | The use of polystyrene latexes in medicine | |
| JPH04208836A (en) | Reaction container kit |